GSK heads to FDA with recently acquired drug from Nuvalent

GSK’s Jideytro posted an impressive response rate of 94% in a first-line treatment for ROS1-positive non-small cell lung cancer patients, according to results shared at the World Conference on Lung Cancer over the weekend. GSK ...